To address the need for improved amyloid classification of intermediate zone cases with a more robust approach, a recent report of a multi-analyte algorithmic test that incorporates both p-Tau 217 and the Aβ42/Aβ40 ratio (along with two other AD-relevant plasma biomarkers) demonstrates that the intermediate zone in diverse populations can be significantly reduced by as much as 3-fold through the inclusion of additional biomarkers (36). This evidence concerns the gene MAPT and Alzheimer disease.